Quality ID #455 (NQF 0213): Percentage of Patients who Died from Cancer Admitted to the Intensive Care Unit (ICU) in the Last 30 Days of Life (lower score – better)
– National Quality Strategy: Effective Clinical Care
– Meaningful Measure Area: Appropriate Use of Healthcare

2020 COLLECTION TYPE:
MIPS CLINICAL QUALITY MEASURES (CQMS)

MEASURE TYPE:
Outcome – High Priority

DESCRIPTION:
Percentage of patients who died from cancer admitted to the ICU in the last 30 days of life.

INSTRUCTIONS:
This measure is to be submitted a minimum of once per performance period for patients who died of cancer during the measurement year. It is anticipated that Merit-based Incentive Payment System (MIPS) eligible clinicians who provide services for patients with the diagnosis of cancer will submit this measure.

Measure Submission Type:
Measure data may be submitted by individual MIPS eligible clinicians, groups, or third-party intermediaries. The listed denominator criteria are used to identify the intended patient population. The numerator options included in this specification are used to submit the quality actions as allowed by the measure. The quality-data codes listed do not need to be submitted by MIPS eligible clinicians, groups, or third-party intermediaries that utilize this modality for submissions; however, these codes may be submitted for those third-party intermediaries that utilize Medicare Part B claims data. For more information regarding Application Programming Interface (API), please refer to the Quality Payment Program (QPP) website.

DENOMINATOR:
Patients who died from cancer

Diagnosis for cancer (ICD-10-CM):
C00.0, C00.1, C00.2, C00.3, C00.4, C00.5, C00.6, C00.8, C00.9, C01, C02.0, C02.1, C02.2, C02.3, C02.4, C02.8, C02.9, C03.0, C03.1, C03.9, C04.0, C04.1, C04.8, C04.9, C05.0, C05.1, C05.2, C05.8, C05.9, C06.0, C06.1, C06.2, C06.80, C06.89, C06.9, C07, C08.0, C08.1, C08.9, C09.0, C09.1, C09.8, C09.9, C10.0, C10.1, C10.2, C10.3, C10.4, C10.8, C10.9, C11.0, C11.1, C11.2, C11.3, C11.8, C11.9, C12, C13.0, C13.1, C13.2, C13.8, C13.9, C14.0, C14.2, C14.8, C15.3, C15.4, C15.5, C15.8, C15.9, C16.1, C16.2, C16.3, C16.4, C16.5, C16.6, C16.8, C16.9, C17.0, C17.1, C17.2, C17.3, C17.8, C17.9, C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19, C20, C21.0, C21.1, C21.2, C21.8, C22.0, C22.1, C22.2, C22.3, C22.4, C22.7, C22.8, C22.9, C23, C24.0, C24.1, C24.8, C24.9, C25.0, C25.1, C25.2, C25.3, C25.4, C25.7, C25.8, C25.9, C26.0, C26.1, C26.9, C30.0, C30.1, C31.0, C31.1, C31.2, C31.3, C31.8, C31.9, C32.0, C32.1, C32.2, C32.3, C32.8, C32.9, C33, C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92, C37, C38.0, C38.1, C38.2, C38.3, C38.4, C38.8, C39.0, C39.9, C40.00, C40.01, C40.02, C40.10, C40.11, C40.12, C40.20, C40.21, C40.22, C40.30, C40.31, C40.32, C40.80, C40.81, C40.82, C40.90, C40.91, C40.92, C41.0, C41.1, C41.2, C41.3, C41.4, C41.9, C43.0, C43.10, C43.111, C43.112, C43.121, C43.122, C43.20, C43.21, C43.22, C43.30, C43.31, C43.39, C43.4, C43.51, C43.52, C43.59, C43.60, C43.61, C43.62, C43.70, C43.71, C43.72, C43.8, C43.9, C44.00, C44.01, C44.02, C44.09, C44.101, C44.1021, C44.1022, C44.1091, C44.1092, C44.111, C44.1121, C44.1122, C44.1191, C44.1192, C44.121, C44.1221, C44.1222, C44.1231, C44.1292, C44.191, C44.1921, C44.1922, C44.1991, C44.1992, C44.201, C44.202, C44.209, C44.211, C44.212, C44.219, C44.221, C44.222, C44.229, C44.291, C44.292, C44.299, C44.300, C44.301, C44.309, C44.310, C44.311, C44.319, C44.320, C44.321, C44.329, C44.390, C44.391, C44.399, C44.40, C44.41, C44.42, C44.49, C44.500, C44.501, C44.509, C44.510, C44.511,
AND

**Patient encounter during the performance period (CPT):** 99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215

**AND**

**Two or more encounters at the reporting site**

**AND**

**Patients who died from cancer:** G9852

### NUMERATOR:

Patients who died from cancer and were admitted to the ICU in the last 30 days of life

**Numerator Instructions:**

**INVERSE MEASURE:** A lower calculated performance rate for this measure indicates better clinical care or control. The “Performance Not Met” numerator option for this measure is the representation of the better clinical quality or control. Submitting that numerator option will produce a performance rate that trends closer to 0%, as quality increases. For inverse measures, a rate of 100% means all of the denominator eligible patients did not receive the appropriate care or were not in proper control.

**Numerator Options:**

- **Performance Met:** Patient admitted to the ICU in the last 30 days of life (G9853)
- **OR**
- **Performance Not Met:** Patient was not admitted to the ICU in the last 30 days of life (G9854)

### RATIONALE:

The American Society of Clinical Oncology (ASCO) recognizes the importance of curtailing aggressive care at the end-of-life period for patients diagnosed with cancer. Unfortunately, studies have suggested that over time, cancer care is becoming more aggressive especially near the end-of-life period. Intensive care unit (ICU) admissions are
often been deemed as an indicator of “aggressive care” and typically used to gauge the quality of care provided to late stage cancer patients.

ASCO advocates for early integration of palliative care/hospice services for patients with late stage cancer in order to avoid aggressive measures at the end of life. With this measure, ASCO hopes providers can evaluate internal processes and make the necessary changes through quality improvement initiatives to ultimately improve a patient’s death experience and improve patient and caregiver/family satisfaction. Additionally, the reduction of ICU admissions at the end of life should reduce overall unnecessary resource utilization costs.

Zhang B, Nilsson ME, Prigerson HG. Factors important to patients’ quality of life at the end of life. Arch Intern Med 2012; 172:1133-1142. Available at: Factors important to patients’ quality of life at the end of life article


CLINICAL RECOMMENDATION STATEMENTS:
2012 ASCO PCO

Seven published randomized trials demonstrate the feasibility of providing various components of palliative care alongside usual oncology care. There is, however, a dearth of data evaluating the integration of modern palliative care practices into standard oncology care, especially in concert with ongoing antitumor therapy. Overall, the addition of palliative care interventions to standard oncology care delivered via different models to patients with cancer provided evidence of benefit.


COPYRIGHT:

The Measure is not clinical guideline, does not establish a standard of medical care, and has not been tested for all potential applications.

The Measure, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measure for commercial gain, or incorporation of the Measure into a product or service that is sold, licensed or distributed for commercial gain.
Commercial uses of the Measure require a license agreement between the user and American Society of Clinical Oncology (ASCO) and prior written approval of ASCO. Contact measurement@asco.org for licensing this measure. Neither ASCO, nor its members shall be responsible for any use of the Measure.

ASCO encourages use of the Measure by other health care professionals, where appropriate.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.

©2019 American Society of Clinical Oncology All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. ASCO, and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.

CPT® contained in the Measure specifications is copyright 2004-2019 American Medical Association. ICD-10 is copyright 2019 World Health Organization. All Rights Reserved.
2020 Clinical Quality Measure Flow for Quality ID #455 NQF #0213:
Percentage of Patients who Died from Cancer Admitted to the Intensive Care Unit (ICU) in the Last 30 Days Of Life (lower score – better)

Disclaimer: Refer to the measure specification for specific coding and instructions to submit this measure.

**SAMPLE CALCULATIONS:**

Data Completeness:

Data Completeness Met (a=40 patients) + Data Completeness Not Met (c=30 patients) = 70 patients = 87.50%

Performance Rate:

Performance Met (a=40 patients) = 40 patients = 57.14%

Data Completeness Numerator (70 patients) = 70 patients

*See the posted measure specification for specific coding and instructions to submit this measure.
A lower calculated performance rate for this measure indicates better clinical control and care.
NOTE: Submission Frequency: Patient-Process
2020 Clinical Quality Measure Flow Narrative for Quality ID #455 NQF #0213:
Percentage of Patients who Died from Cancer Admitted to the Intensive Care Unit (ICU) In the Last 30 Days of Life (lower score – better)

Disclaimer: Refer to the measure specification for specific coding and instructions to submit this measure

1. Start with Denominator

2. Check Diagnosis:
   a. If Diagnosis for Cancer as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
   b. If Diagnosis for Cancer as Listed in the Denominator equals Yes, proceed to Encounter Performed.

3. Check Encounter Performed:
   a. If Encounter as Listed in the Denominator equals No, do not include in Eligible Population. Stop Processing.
   b. If Encounter as Listed in the Denominator equals Yes, proceed to check Two or More Encounters at the Reporting Site.

4. Check Two or More Encounters at the Reporting Site:
   a. If Two or More Encounters at the Reporting Site equals No, do not include in Eligible Population. Stop Processing.
   b. If Two or More Encounters at the Reporting Site equals Yes, proceed to check Patients who Died from Cancer.

5. Check Patients who Died from Cancer:
   a. If Patients who Died from Cancer equals No, do not include in Eligible Population. Stop Processing.
   b. If Patients who Died from Cancer equals Yes, include in Eligible Population.

6. Denominator Population:
   a. Denominator Population is all Eligible Patients in the Denominator. Denominator is represented as Denominator in the Sample Calculation listed at the end of this document. Letter d equals 80 patients in the Sample Calculation.

7. Start Numerator

8. Check Patient Admitted to The ICU in the Last 30 Days of Life:
   a. If Patient Admitted to the ICU in the Last 30 Days of Life equals Yes, include in Data Completeness Met and Performance Met.
   b. Data Completeness Met and Performance Met letter is represented in the Data Completeness and Performance Rate in the Sample Calculation listed at the end of this document. Letter a equals 40 patients in the Sample Calculation.
c. If Patient Admitted to the ICU in the last 30 Days of Life equals No, proceed to check Patient Was Not Admitted to the ICU in the Last 30 Days of Life.

9. Check Patient Was Not Admitted to the ICU in the Last 30 Days of Life:

a. If Patient Was Not Admitted to the ICU in the Last 30 Days of Life equals Yes, include in Data Completeness Met and Performance Not Met.

b. Data Completeness Met and Performance Not Met letter is represented in the Data Completeness in the Sample Calculation listed at the end of this document. Letter c equals 30 patients in the Sample Calculation.

c. If Patient Was Not Admitted to the ICU in the Last 30 Days of Life equals No, proceed to check Data Completeness Not Met.

10. Check Data Completeness Not Met:

a. If Data Completeness Not Met, the Quality Data Code or equivalent was not submitted. 10 patients have been subtracted from the Data Completeness Numerator in the Sample Calculation.

<table>
<thead>
<tr>
<th>SAMPLE CALCULATIONS:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Data Completeness</strong>=</td>
</tr>
<tr>
<td>Performance Met (a=40 patients) - Performance Not Met (c=30 patients) = 70 patients = 87.50%</td>
</tr>
<tr>
<td>Eligible Population / Denominator (d=80 patients) = 80 patients</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Performance Rate=</th>
</tr>
</thead>
<tbody>
<tr>
<td>Performance Met (a=40 patients) = 40 patients = 57.14%</td>
</tr>
<tr>
<td>Data Completeness Numerator (70 patients) = 70 patients</td>
</tr>
</tbody>
</table>